CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 1,101–1,200 of 1,725
Gene therapy for inborn errors of immunity: past progress, current status and future directions
Torrance, R. W., Orf, K., & Fox, T. A. (2025) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2025.42 · Cited by 8
“Two notable examples, at the advanced stage of clinical development, include adeno-associated virus-based therapies for haemophilia [127,128] and lipid-nanoparticle CRISPR therapy for congenital amyloidosis [129] .”
Therapeutic base editing to generate a gain-of-function F9 variant for hemophilia B
Baatartsogt, N., Kashiwakura, Y., Hiramoto, T., Ito, R., Sato, R., Nagao, Y., Naruoka, H., Takata, H., Hayakawa, M., Batjargal, K., et al. (2025) · Blood · doi:10.1182/blood.2024027870 · Cited by 6
“23 The number of predicted off-target sites was summarized by mismatch count, incorporating all mismatch and bulge combinations, to compare specificity profiles.”
Liu, Y., & Riaz, M. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12110434 · Cited by 3
“Genomic manipulation provides a powerful opportunity to understand how iPSCs derived from patients with known amyloid mutations, especially TTR-ACM, can help study amyloid disease phenotypes in an isogenic background [84–86] (Figure 2).”
Mechanisms and Therapies of Hypertrophic Cardiomyopathy
Pietsch, N., Singh, S. R., & Carrier, L. (2025) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042224-093244 · Cited by 4
Gong, J. D., Samarkhazan, H. S., Siavashi, M., Servatian, N., & Pirsavabi, F. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11235-2 · Cited by 5
The Impact of QSP Modeling on the Design and Optimization of Gene Therapy Approaches
Rayad, N., Chowdhury, E. A., & Meno‐Tetang, G. M. L. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70131 · Cited by 4
Genome editing of Spp1 by inhalable CRISPR/Cas9 formulation for treating pulmonary fibrosis
Bao, W., Ji, P., Xi, W., Ganzorig, C., Liu, Z., & Ping, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114424 · Cited by 4
Heendeniya, S. N., Chen, S., Bhatti, S. H., Zahra, Q. U. A., Rahimizadeh, K., Poudel, B. H., Wilton, S. D., & Veedu, R. N. (2025) · Experimental Biology and Medicine · doi:10.3389/ebm.2025.10784 · Cited by 4
Chemical engineering strategies to enhance mRNA–LNP stability for therapeutic applications
Zhang, Z., Ong, Y., Yang, B., Fan, B., Yang, Y. Y., & Ni, Q. (2026) · Biomaterials Science · doi:10.1039/d5bm01635e · Cited by 7
RNA ‐Based Therapies for Inherited Metabolic Disorders
Reddy, S. V., Gurung, S., Ghosh, R., Mills, P. B., Baruteau, J., & Zhou, H. (2026) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70150 · Cited by 7
“This trial involved administering an LNP encapsulating mRNA for the Cas9 protein and a single guide RNA targeting TTR in a small group of patients with hATTR amyloidosis (NCT04601051) [208].”
The application of CRISPR-Cas9 system in brain diseases
Miao, Y., Li, C., Su, Y., Peng, T., Wang, J., Liu, S., Ma, C., Li, L., & Wang, Y. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2629031 · Cited by 3
Non-viral delivery of genome-editing tools for treatment of genetic disorders
Yang, J., Chen, Y., Chen, X., & Ping, Y. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.02.014 · Cited by 3
“Transthyretin amyloidosis (ATTR amyloidosis) is a severe disorder primarily characterized by neuropathy and/or cardiomyopathy 97-99 , occurring in both hereditary and wild-type forms 100 .”
Minimizing far-extending chromatin perturbation in genome editing preserves stem cell identity
Zhu, M., Yuan, J., Meng, Q., Yu, J., Xu, X., Xu, M., Ren, X., Hu, Y., Wei, G., Jia, Z., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.01.015 · Cited by 3
Kinoshita, M., Kawaguchi, K., Mochida, Y., Le, N. B. T., Kainuma, A., Takeda-Miyata, N., Kojima, M., Sawa, T., & Uchida, S. (2026) · Nature Communications · doi:10.1038/s41467-026-71040-8 · Cited by 4
“This approach has shown promise in clinical trials for genome editing and protein replacement therapies 19 – 21 .”
mRNA medicine for cardiovascular disease
Zhou, Z., Chen, W., Yu, H., Tabas, I. A., Foo, R., & Tao, W. (2026) · Nature Cardiovascular Research · doi:10.1038/s44161-026-00804-8 · Cited by 6
On the road to in vivo CAR-T success: Comparing promising viral and non-viral vectors
de la Mota, S., Suchet, L., van Wijk, M., Stibbs, D. J., Couto, P. S., & Rafiq, Q. A. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108907 · Cited by 6
Sharma, P., Thuy, N. P., Ansari, I. H., Tripathi, R. M., Kala, M., Elberry, M. H., Sharma, N., & Lee, S. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03720-8 · Cited by 4
“This approach achieved dose-dependent and durable reductions in disease-causing protein levels, providing a proof of principle for systemic in vivo genome editing in patients [195].”
Re-balancing immunity with CRISPR-Cas9: Novel strategies for cancer and autoimmune disorders
Ren, X., Zhou, Z., Kong, L., Guo, Y., Liu, Y., Li, J., Gu, X., Jiang, C., & Wu, J. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108921 · Cited by 3
Visualizing the Nucleome Using the CRISPR–Cas9 System: From in vitro to in vivo
Maloshenok, L. G., Abushinova, G. A., Ryazanova, A. Y., Bruskin, S. A., & Zherdeva, V. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923140080 · Cited by 4
Tafamidis in the Treatment of ATTR-related Cardiomyopathy
Capovilla, T. M., Lalario, A., Rossi, M., Porcari, A., Aimo, A., Limongelli, G., Emdin, M., Merlo, M., & Sinagra, G. (2024) · Heart Failure Clinics · doi:10.1016/j.hfc.2024.03.007 · Cited by 3
Samson, C., du Rand, A., Hunt, J., Whitford, W., Jacobsen, J. C., & Sheppard, H. M. (2024) · Journal of the Royal Society of New Zealand · doi:10.1080/03036758.2024.2347968 · Cited by 5
“So far, the treatment of HIV, genetic blindness (Sundaresan et al. 2023), cardiovascular disease (Naddaf 2023), β -thalassaemia (Fu et al. 2022) and transthyretin amyloidosis (Gillmore et al. 2021) are showing promise.”
Preexisting maternal immunity to AAV but not Cas9 impairs in utero gene editing in mice
Riley, J. S., Luks, V. L., Berkowitz, C. L., Dumitru, A. M., Kus, N. J., Dave, A., Menon, P. V., Paepe, M. E. D., Jain, R., Li, L., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179848 · Cited by 7
“While alternative, less immunogenic delivery vehicles (34) may someday circumvent preexisting AAV immunity in adults, Cas9 remains the backbone of many in vivo editing strategies, including base editing, being investigated in clinical trials (35, 36).”
Precision Genetic Therapies: Balancing Risk and Benefit in Patients with Heart Failure
Johnston, J. R., & ADLER, E. D. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02096-5 · Cited by 4
“Preclinical studies in rodent models and nonhuman primates demonstrated that a single intravenous infusion of NTLA-2001 led to reductions in transthyretin levels that persisted over at least a 12-month period [91, 92].”
BackgroundRecent development in CRISPR-Cas systems for cardiac disease
Munshi, I. D., Acharya, M., Mukherjee, S., & Mani, I. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.08.004 · Cited by 6
Hsueh, H., Chao, C., Lin, Y., Tseng, P., Su, M.-Y. M., & Hsieh, S. (2024) · Journal of Internal Medicine · doi:10.1111/joim.20019 · Cited by 3
Simões, M. V., Fernandes, F., Dabarian, A. L., Valicelli, F. H., & Mesquita, C. T. (2024) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20240112 · Cited by 3
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy
Lane, I. C., & Jan, M. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.04.001 · Cited by 3
The Utilization of CRISPR/Cas9 in Monogenic Disorders Authors
Mellor, S. M. (2022) · Spectra Undergraduate Research Journal · doi:10.9741/2766-7227.1018 · Cited by 4
Belova, L., Demchenko, A. G., Kochergin-Nikitsky, K. S., Kondrateva, E. V., Slesarenko, Y. S., Salikhova, D. I., Лавров, А. В., Efremova, A. S., Bukharova, T. B., Goldshtein, D. V., et al. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00668-4 · Cited by 3
“With the advent of genome editing methods, gene therapy received a new impetus for development [1].”
Bastaki, K., Umlai, U. I., & Jithesh, P. V. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99924-3.00004-2 · Cited by 5
Gene therapy of cardiomyopathies: opportunities and current perspectives
Лавров, А. В., & Zaklyazminskaya, E. V. (2023) · Clinical and Experimental Surgery Petrovsky journal · doi:10.33029/2308-1198-2023-11-1-32-46 · Cited by 4
CRISPR-Directed Gene Editing as a Method to Reduce Chemoresistance in Lung Cancer Cells
Rivera-Torres, N., Bialk, P. A., & Kmiec, E. B. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3163-8_18 · Cited by 4
Minh, N. N. T., Begum, A., Zhang, J., Leira, P., Todarwal, Y., Linares, M., Norman, P., Derbyshire, D. J., von Castelmur, E., Lindgren, M., et al. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c02147 · Cited by 2
Chen, Y., Song, Y., Zhu, X., Dong, C., & Chen, M.-S. (2023) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2023.2281462 · Cited by 3
CRISPR-Cas9 for the Treatment of Transthyretin Cardiac Amyloidosis
Panichella, G., & Aimo, A. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128267417231127070901 · Cited by 3
Towards etiological treatments in cardiomyopathies
Lairez, O., Fournier, P., Itier, R., Bachelet, B., Huart, A., & Cariou, E. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104223 · Cited by 3
Gene-based therapies for neuromuscular disorders
Zanoteli, E., França, M. C., & Marques, W. (2024) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1777755 · Cited by 9
Biomaterial-assisted therapeutic cell production and modification in vivo
Dai, K., Wang, J., & Liu, C. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104192 · Cited by 4
An epigenetic editor to silence genes
Whittaker, M. N., & Musunuru, K. (2024) · Science · doi:10.1126/science.adq3334 · Cited by 5
What Rodent Models Teach Us about the Association of Autism and Epilepsy
Golshani, P. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197549469.003.0059 · Cited by 3
Genetics of the Cardiomyopathies: A Review for the Cardiologist
Scolari, F. L., Garbin, H. I., Beuren, T. M. A., et al. (2024) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20240047i · Cited by 3
“61 The promising perspective indicates that the future of transthyretin amyloidosis treatment may be based on developing and refining gene editing techniques, bringing a new horizon to the management of this pathology.”
Sundnes, M. L., Swaminathan, P., Lindgren, M., et al. (2024) · ChemPhotoChem · doi:10.1002/cptc.202400249 · Cited by 3
Nucleic acid delivery as a therapeutic approach for cancer immunotherapy
Wilson, K., Garima, & Dhanawat, M. (2024) · Advances in immunology · doi:10.1016/bs.ai.2024.10.009 · Cited by 4
Multifaceted pulmonary manifestations of amyloidosis: state-of-the-art update
Charokopos, A., Baqir, M., Roden, A. C., et al. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2457374 · Cited by 3
“Finally, clinical research involving CRISPR-Cas9 gene editing in ATTRv is still in its early stages [71].”
Antibody ALXN2220 (Formerly NI006) for the Treatment of Transthyretin Cardiac Amyloidosis
Pillai, A. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000934 · Cited by 3
Asteggiano, C., Paoletti, M., Vegezzi, E., Xeni, D., Santini, F., Bergsland, N., Papinutto, N., Todisco, M., Cosentino, G., Cortese, A., et al. (2025) · European Journal of Neurology · doi:10.1111/ene.70172 · Cited by 3
Rewriting the script: gene therapy and genome editing for von Willebrand Disease
Barraclough, A., Bär, I., van Duijl, T. T., Fijnvandraat, K., Eikenboom, J. C. J., Leebeek, F. W. G., Bierings, R., Voorberg, J., & Trasanidou, D. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1620438 · Cited by 4
Prinzipien der translationalen Gentherapie für neuromuskuläre Erkrankungen
Schoser, B. G. H. (2022) · Der Nervenarzt · doi:10.1007/s00115-022-01287-1 · Cited by 3
Transthyretin amyloidosis: the picture is getting clearer
Musigk, N., & Heidecker, B. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2641 · Cited by 3
Advances in genetic, epigenetic and environmental aspects of rare liver diseases
Andersson, E. R., & Lohse, A. W. (2021) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2021.104411 · Cited by 3
Consensus too soon: judges’ and lawyers’ views on genetic information use
Selita, F., Chapman, R., Kovas, Y. V., Smereczynska, V., Likhanov, M. V., & Toivainen, T. (2023) · New Genetics and Society · doi:10.1080/14636778.2023.2197583 · Cited by 4
“2021; Gillmore et al .”
Leveraging microRNAs for cellular therapy
Hasiuk, M., Dölz, M., Marone, R., & Jeker, L. T. (2023) · Immunology Letters · doi:10.1016/j.imlet.2023.08.005 · Cited by 3
Scherer, S. S., Kleopa, K. A., Rossor, A. M., & Reilly, M. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00006-6 · Cited by 3
The promise and challenges of precision medicine in dilated cardiomyopathy
Mason, S., Quinn, E., & Halliday, B. P. (2021) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytab391 · Cited by 3
“protein kinase has shown potential to modify the disease course of laminopathies in both animal and human studies.(9) Gene editing therapies also offer huge promise in improving the outcome of patients with malignant genetic disease over the next 5–10 years.”
BackgroundChen, C. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101372 · Cited by 3
Editorial: Genome Editing to Treat Cystic Fibrosis and Other Pulmonary Diseases
Vaidyanathan, S., & Ryan, A. L. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.917916 · Cited by 3
“…treat inherited blood disorders (NCT03655678, NCT04208529, NCT04853576, NCT04925206, NCT04819841, NCT04774536) and in vivo genome editing of the liver to treat Transthyretin amyloidosis (ATTR, NCT04601051) or Hereditary Angioedema (HAE, NCT05120830) (Frangoul et al., 2021; Gillmore et al., 2021).”
BackgroundIn Vivo CRISPR Gene Editing in Patients with Herpes Stromal KeratitisPreprint
Wei, A., Yin, D., Zhai, Z., Ling, S., Le, H., Tian, L., Xu, J., Paludan, S. R., Cai, Y., & Hong, J. (2023) · medRxiv · doi:10.1101/2023.02.21.23285822 · Cited by 3
“in which CRISPR was used for in vivo treatment of transthyretin amyloidosis (28).”
MethodRabinowitz, R., Shor, O., Zerbib, J., Herman, S., Zelikson, N., Madiwale, S., Yom-Tov, N., Ben‐David, U., Benninger, F., & Offen, D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.11.536265 · Cited by 3
“As CRISPR-based therapeutics show promising results in clinical trials 49 – 52 and move forward toward applicable solutions to treat genetic conditions, engineered Cas enzymes have a great potential to increase the safety of such treatments by reducing unintended off-target activity.”
BackgroundKim, J., Jozić, A., Bloom, E., Jones, B., Marra, M., Murthy, N. T. V., Eygeris, Y., & Sahay, G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.17.576136 · Cited by 3
“Given the expanding application of mRNA in gene editing 24,25 , the interest in achieving highly accurate delivery through inhalation has grown substantially, particularly for its potential to offer a lasting solution to inherited lung disorders.”
BackgroundDiseases of the Peripheral Nerves
Lunn, M. P., Rossor, A. M., & Reilly, M. M. (2024) · Wiley eBooks · doi:10.1002/9781119715672.ch16 · Cited by 4
Long term rescue of Alzheimer’s deficits in vivo by one-time gene-editing of App C-terminusPreprint
Aulston, B. D., Gimse, K., Bazick, H., Kramár, E. A., Pizzo, D. P., Shavarebi, F., Rust, T., Rosa, S. G., Parra‐Rivas, L. A., Sun, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.08.598099 · Cited by 8
Large Serine Integrase Off-Target Discovery with Deep Learning for Genome Wide PredictionPreprint
Bakalar, M. H., Biondi, T. C., Liang, X., Santesmasses, D., Bara, A. M., Mehta, J. B., Wang, J., Hazelbaker, D. Z., Finn, J. D., & O’Connell, D. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.10.617699 · Cited by 4
“This two-step strategy was inspired by the approaches pioneered for the first Cas9 genome editing therapies 24, 26, 31 , because the risk of off-target editing from Cas9 and LSIs are both dependent on DNA sequence homology 22, 32 .”
BackgroundMethodSelf-citationMinimization of gene editing off-target effects by tissue restriction of expressionPreprint
Kim, N., Aubert, M., Haick, A. K., Massa, P. A., Loprieno, M. A., Walter, M., Kim, H. G., Nunley, B. E., Xie, H. J., Stensland, L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.21.634017 · Cited by 4
A comprehensive analysis of the use of nucleoside analogues in RNA therapeutics
Kukushkina-Zvezdova, A. A., Zherebtsova, A. A., Telegina, D. V., Skvortsov, I. A., Ivanov, R. A., & Reshetnikov, V. V. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08083-4 · Cited by 3
RNA therapeutics: Molecular mechanisms, and potential clinical translations
Nguyen, T. T., Thi, Y.-V. N., & Chu, D. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.012 · Cited by 2
Hainsworth, A. H., Blackburn, T. P., Bradshaw, E. M., Elahi, F. M., Gorelick, P. B., Isaacs, J. D., Wallin, A., & Williams, S. (2024) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2024.100364 · Cited by 6
Fine, N. M., Ducharme, A., Matte, G., et al. (2025) · CJC Open · doi:10.1016/j.cjco.2025.03.002 · Cited by 2
“49,50 As the treatment landscape for mixed phenotype ATTRv amyloidosis evolves, factors such as drug access, availability, route and frequency of administration, and safety pro fi le will play a larger role in treatment selection.”
Yuan, Z., Luozhong, S., Li, R., Gu, W., Chen, Y., Bhashyam, D., Lai, R., & Jiang, S. (2025) · ACS Nano · doi:10.1021/acsnano.5c02001 · Cited by 7
Xiong, Q., Tremblay, F., & Marlowe, J. L. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.012 · Cited by 2
Modell, S. M., Smith, J. A., & Kardia, S. L. R. (2025) · Public Health Genomics · doi:10.1159/000546850 · Cited by 2
“In a study of 6 patients with hereditary trans-thyretin (TTR) amyloidosis polyneuropathy, the first 28 days post-infusion elicited few adverse events and a 52% mean reduction in serum TTR levels for lower dose participants [10].”
Catalytic-state structure of Candidatus Hydrogenedentes Cas12b revealed by cryo-EM studies
Li, Y., Li, J. J., Pei, X., Wei, J., Gan, J., & Lin, J. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf519 · Cited by 2
“Moreover, assisted by a proprietary lipid nanoparticle (LNP) or other delivery system, Sp-Cas9 has also been investigated in the treatment of some fatal diseases in clinic, such as transthyretin amyloidosis [ 14 ].”
Acquired and Genetic Amyloid Neuropathies
Karam, C., Pasnoor, M., Barohn, R. J., & Dimachkie, M. M. (2025) · Neurologic Clinics · doi:10.1016/j.ncl.2025.05.016 · Cited by 2
In vivo gene therapy: A strategy for mutations, degenerations, and tumors
Wang, T., Yu, M., Liu, P., Song, Z., Li, C., Yang, J., & Liu, N. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101808 · Cited by 6
“In the phase I clinical trial, including six transthyretin amyloidosis patients treated with NTLA-2001, the serum TTR protein concentration reduced by 52% on average in the group treated with 0.1 mg per kilogram and by 87% on average in the group treated with 0.3 mg per kilogram on day 28.”
InfluentialBatho, C. A. P., Hudson, J. E., & Wilson, C. H. (2025) · Biochemical Society Transactions · doi:10.1042/bst20243001 · Cited by 3
“However, only recently has modRNA been utilised to deliver the Cas9 mRNA with in vivo gene editing applied to treating transthyretin amyloidosis [48] and hereditary angioedema [136].”
Pioneering next-generation mRNA therapeutics through molecular engineering and delivery optimization
Qi, L., Li, Z., Feng, Z., Liu, J., & Chen, X. S. (2025) · Materials Today · doi:10.1016/j.mattod.2025.08.023 · Cited by 3
Dieu, D. C., Pernice, H. F., Muratovic-Colic, H., Wetzel, P. J., Barzen, G., Wieder, N. W., Werhahn, S. M., Heidecker, B., Spethmann, S., & Hahn, K. (2025) · Neurological Research and Practice · doi:10.1186/s42466-025-00428-6 · Cited by 2
“As of June 2025, a multitude of treatment strategies are available in the treatment of ATTRv-amy-loidosis, ranging from: FDA/EMA-approved drugs [18– 24], to off-label use of repurposed drugs [25] as well as novel agents currently under clinical development [26, 27].”
Cancer gene therapy: historical perspectives, current applications, and future directions
Zeng, J., Luo, J., & Zeng, Y. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01712-z · Cited by 7
“…disease, as evidenced by the adaptation of its sgRNA design principles for tumor suppressor genes like TP53 and the reformulation of LNP delivery systems from ocular to intravenous administration routes, enabling systemic CRISPR delivery in current cancer clinical trials (Gillmore et al. 2021 ).”
Shamsi, A., Alrouji, M., AlOmeir, O., Tasqeruddin, S., Khuzin, D., & Zuberi, A. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1681891 · Cited by 5
“Two examples of such ongoing CRISPR-mediated clinical trials in humans include EDIT-101 (Pierce et al., 2024) (Leber Congenital Amaurosis, LCA) and NTLA-2001 (Gillmore et al., 2021) (Transthyretin (ATTR) Amyloidosis).”
Gene Therapy for Inherited Cardiac Arrhythmias
Turkieltaub-Paredes, M., Hulsurkar, M., & Wehrens, X. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10716-w · Cited by 1
“In addition, LNPs have been tested in small cohorts of patients with transthyretin amyloidosis, a life-threatening disease characterized by progressive accumulation of a misfolded transthyretin protein in nerves and the heart [90].”
Yamada, K., Suzuki, T., & Farsad, K. (2025) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2025.08.037 · Cited by 2
Cardiac amyloidosis: consensus of the Eurasian Association of Cardiologists (EAC)
Жиров, И. В., Николаевна, Н. С., Моисеева, О. М., Rekhtina, I. G., Suponeva, N. A., Ansheles, A. A., Барбараш, О. Л., Galyavich, A. S., Duplyakov, D. V., Zateyshchikov, D. A., et al. (2025) · Eurasian heart journal · doi:10.38109/2225-1685-2025-4-6-39 · Cited by 5
Expanding the CRISPR/Cas toolkit: applications in proteomics and theranostics
Punde, A., Dey, S., Pandire, R., Bhattacharjee, A., & Patra, C. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1713700 · Cited by 2
Sun, Y., Sun, X. C., Liu, H., & Luo, F. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.217412 · Cited by 2
Sharma, A., Khushika, K., Chaudhary, M., Jana, P. K., & Parveen, N. (2025) · Nanoscale · doi:10.1039/d5nr03142g · Cited by 3
Lyu, G., Li, P., & Lang, W. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07066-1 · Cited by 4
“Adminis-tering NTLA-2001 to a limited group of individuals with familial ATTR amyloidosis and polyneuropathy resulted in reduced blood TTR protein concentrations by targeted deletion of TTR, with only moderate side effects reported (NCT04601051) [120].”
Kim, K., Lee, C., Lim, N., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02576 · Cited by 2
Jin, X., Wu, X., Song, J., Luo, M., Ye, Q., Ren, C., Li, S., Li, M., Hu, M., An, Y., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.012 · Cited by 3
Integrating synthetic biology to understand and engineer the heart, lung, blood, and sleep systems
Chaikof, E. L., Chen, J., Gillette, M. U., Boyer, L. A., Deans, T. L., Li, P., Hilton, I. B., Daniels, K. G., Goyal, Y., Mei, Y., et al. (2025) · Cell Systems · doi:10.1016/j.cels.2025.101446 · Cited by 2
Nanoparticle-enhanced CRISPR delivery: paving the path for in vivo tumor gene editing
Khizar, M., Aminpoor, H., Zaib, M., et al. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004414 · Cited by 2
“The NTLA-2001 trial provided the first clinical evidence that CRISPR could be delivered safely to human hepatocytes using LNPs, establishing a milestone for in vivo genome editing [ 1 ] .”
Cardiolipin-Based Nanoparticles Inhibit α-Synuclein Fibrilization
Stykel, M. G., Medeiros, J., Ryan, T. L., Siripala, S. V., Carmago, S., Lu, P., Bamm, V. V., Coackley, C. L., & Ryan, S. D. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00688 · Cited by 3
CRISPR in Medicine: A Systematic Review of Clinical Trials and Therapeutic Applications
Rahmanian, M., Khoshandam, M., Mousazadeh, M., Yang, P., Soltaninejad, H., Dehkordi, P. K., Sadeghizadeh, M., Goudarzi, M. T. H., Azimi, A. H., & Sheykhhasan, M. (2026) · Human Gene Therapy · doi:10.1177/10430342251409714 · Cited by 8
“37 In contrast to conventional lifelong management tactics, these fi ndings demonstrated the possibility of in vivo CRISPR/Cas9 editing for long-lasting therapeutic bene fi ts in hereditary diseases, providing a single-dose curative strategy.”
Technology for Nucleic Acid Delivery in the Treatment of Hematological Malignancies
Dezfouli, S. A., Uludağ, H., Nasrullah, M., Rajendran, A. P., & Remant, K. C. B. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115780 · Cited by 3
Xin, C., Xiang, G., Cao, S., Wang, Y., Yuan, S., Liu, X., Huo, Y., Sun, J., Wan, X., Liu, D., et al. (2026) · Genome biology · doi:10.1186/s13059-026-03949-8 · Cited by 5
“CRISPR technology holds great potential in clinical translation [1–6], exemplified by the approval of the world’s first CRISPR gene editing therapy (Casgevy) by the MHRA and FDA at the end of 2023 [7, 8].”
Overview of gene editing strategies against HBV
Janetzki, Z. T., McCoullough, L. C., Revill, P. A., & Littlejohn, M. (2026) · Antiviral Research · doi:10.1016/j.antiviral.2026.106355 · Cited by 4
Ali, K., Awad, M. K., Majeed, H., Amer, M. S., Alayyat, A., Ali, A. E., Ali, A., & Abuzaid, A. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm42153 · Cited by 4
“Early-phase trials of CRISPR-based gene editing (e.g., NTLA-2001) have shown promising results in reducing transthyretin levels, but this approach remains investigational at present [109].”
Du, C., Gao, H., Jia, F., Zhao-lin, D., & Fang, W. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01407 · Cited by 2
Plant-Based Nanotechnology for Proteomic and Genomic: Current Trends, Approaches and Applications
Abrar, S., & Naik, M. R. (2026) · Smart nanomaterials technology · doi:10.1007/978-981-95-4709-8_12 · Cited by 4
Engineered cargo-free nanoparticle decoys for phagocytic modulation of macrophages
Panovich, P. M., Ganesan, A., Markey, A. I., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114699 · Cited by 2
“…non-viral nucleic acid delivery has been demonstrated recently by the COVID-19 lipid nanoparticle (LNP)-based vaccines as an intramuscular injection [1], the drug patisiran targeting hepatocytes in the liver [2], and pre-clinical data demonstrating gene editing in vivo mediated by CRISPR/Cas9 [3].”
Application of Omics Analysis in the Clinical Practice and Research of Transthyretin Amyloidosis
Moriyama, H., Shaikh, F. A., & Yokota, T. (2026) · Genes · doi:10.3390/genes17030333 · Cited by 2
“NTLA-2001, an in vivo gene-editing therapeutic based on CRISPR–Cas9 technology, is being developed with the goal of “One-and-done” treatment via permanent TTR knockdown through a single dose, raising hopes for liberation from the burden of lifelong treatment [24,25].”
Recent Advances in the Non-viral Delivery of Genes to Central Nervous System Disorders
Marei, H. E. S. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01703-z · Cited by 4
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



